687-51-4

Basic information

• Product Name: H-LEU-NH2
• Synonyms: leucinamide;H-LEU-NH2;LEUCINE-NH2;L-LEUCINE AMIDE;(S)-2-amino-4-methylvaleramide;(S)-2-Amino-4-methylpentanamide;L-Leu-NH2;(2S)-2-amino-4-methylpentanamide
• CAS NO: 687-51-4
• Molecular Formula: C₆H₁₄N₂O
• Molecular Weight: 130.19
• EINECS: 211-696-2
• Mol File: 687-51-4.mol
• Article Data: 21

Chemical Properties

• Melting Point: 84-85 °C(Solv: benzene (71-43-2); ethanol (64-17-5)(10:1))
• Boiling Point: 250.9±23.0 °C(Predicted)
• Appearance: /
• Density: 0.980±0.06 g/cm3(Predicted)
• Storage Temp.: -15°C
• PKA: 16.08±0.50(Predicted)
• CAS DataBase Reference: H-LEU-NH2(CAS DataBase Reference)
• NIST Chemistry Reference: H-LEU-NH2(687-51-4)
• EPA Substance Registry System: H-LEU-NH2(687-51-4)

Safety Data

• Hazardous Substances Data: 687-51-4(Hazardous Substances Data)

Usage

Chemical Properties

White crystalline powder

Definition

ChEBI: An amino acid amide that is L-leucine in which the carboxy OH group is replaced by NH2.

InChI:InChI=1/C6H14N2O/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H2,8,9)/t5-/m0/s1

Upstream product

• 70533-96-9 N-tert-butoxycarbonyl-(L)-leucinamide 
• 61-90-5 L-leucine 
• 106827-71-8 Trt-L-Hse(Trt)-L-Leu-NH₂ 
• 13079-20-4 2-Amino-4-methyl-pentanoic acid amide 
• 10466-61-2 (2S)-amino-4-methylpentanamide hydrochloride 
• 139551-97-6 (S)-(9H-fluoren-9-yl)methyl (1-Amino-4-methyl-1-oxo-pentan-2-yl)carbamate 
• 35661-60-0 Fmoc-Leu-OH 
• 3350-19-4 (tert-butoxycarbonyl)-L-leucine p-nitrobenzylester 
• 2666-93-5 (S)-Leu-OMe 
• 13139-15-6 N-tert-butoxycarbonyl-L-leucine 
• 869-19-2 Glycyl-L-leucine 
• 7664-41-7 ammonia 
• 60117-24-0 H-Tyr-Gly-Gly-Phe-Leu-NH₂ 
• 65356-77-6 N-acetyl-L-triptophanyl-L-leucine amide 

Downstream Products

• 17193-48-5 Z-(β-O-Bz-Asp)-Leu-NH2 
• 129155-64-2 (S)-2-{[1-(4-Methoxy-phenyl)-meth-(E)-ylidene]-amino}-4-methyl-pentanoic acid amide 
• 69193-15-3 N-(benzyloxycarbonyl)-glycyl-L-phenylalanyl-L-leucine amide 
• 7535-72-0 (N-carboxybenzylglycinyl)leucinamide 
• 17331-87-2 Z-L-Ser-L-Leu-NH₂ 
• 38678-59-0 L-Phe-L-Leu-NH₂ 
• 69193-13-1 Cbz-L-Phe-L-Leu-NH₂ 
• 126028-17-9 BocTyrLeuNH₂ 
• 66127-57-9 Bz-Arg-Leu-NH₂ 
• 126028-18-0 Boc(D)TyrLeuNH₂ 
• 219309-96-3 C₂₆H₃₄N₄O₄S₂ 
• 28529-34-2 N-acetyl-L-leucine amide 
• 74257-73-1 tert-butyl ((S)-1-(((S)-1-amino-4-methyl-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate 

Relevant articles and documents

Enzymatic stability of myostatin inhibitory 16-mer peptides

-

HEMIAMINAL-TAG FOR PROTEIN LABELING AND PURIFICATION

The invention pertains to the synthesis, isolation, and characterization of hemiaminal for selective labeling of peptides, proteins, antibodies, and organic fragments with -C(=0) CH2NH2 and derivatives with -CH2NH2 group over -C(=0) CHRNH2 group (where R≠H). The invention also pertains to the method of single-site immobilization of proteins through N-terminus Gly on solid phase. The invention includes late-stage tagging of N-terminus Gly with an affinity tag, 19F NMR probe, and a fluorophore and a method for metal-free protein purification and isolation of analytically pure proteins.

AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES

The present invention relates to medicine and includes a method for preventing and treating diseases caused by RNA- and DNA-containing viruses, and concomitant diseases, wherein the method comprises the use of an effective amount of compounds of general formula I or pharmaceutically acceptable salts thereof. The invention also relates to methods for preparing said compounds, pharmaceutical compositions for the prevention or treatment of diseases caused by RNA- and DNA-containing viruses, said compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof. The invention addresses the object of providing a novel agent effective in the treatment of diseases caused by an RNA-containing virus belonging to the Enterovirus, Metapneumovirus, Pneumovirus, Respirovirus, or Alfa-coronavirus genus, and/or by a DNA-containing virus belonging to the Adenoviridae and/or Herpesviridae family, and in the prevention and treatment of asthma exacerbation, chronic obstructive pulmonary disease, mucoviscidosis, conjunctivitis, gastroenteritis, hepatitis, myocarditis; in the prevention and treatment of rhinorrhea, acute and infectious rhinitis, pharyngitis, nasopharyngitis, tonsillitis, laryngitis, laryngotracheitis, laryngotracheobronchitis, bronchitis, bronchiolitis, pneumonia, or airway obstructive syndrome.